Stay updated with the Cipla Stock Liveblog, your one-stop destination for real-time information and analysis of a leading ...

Join us on the Cipla Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay in ...

Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday, helped by strong demand in its domestic market which overshadowed weak sales in ...

Cipla's earnings before interest, tax, depreciation, and amortisation (EBITDA) jumped nearly 16% year-on-year to Rs 1,989 crore, according to the statement.

>> Long build up is seen in CIPLA Futures, where we have seen 4 per cent rise in the open interest on the day when Cipla ...

Cipla share price will remain in focus after the United States Food and Drug Administration (USFDA) has classified the ...

The USFDA has conducted routine cGMP inspection at the facility in the period between November 7 through November 13, 2024.

Mumbai: Cipla has announced that the Company will invest approx. ZAR 900 million in equity share capital of Cipla Medpro ...

Pharma major Cipla Ltd on Tuesday posted its highest-ever quarterly revenue and Ebitda margin, as robust sales in India, Europe and emerging markets outweighed weakness in its US business.

Cipla Ltd is quoting at Rs 1456.1, up 2.26% on the day as on 12:49 IST on the NSE. The stock is up 7.78% in last one year as compared to a 7.07% spurt in NIFTY and a 19.04% spurt in the Nifty Pharma ...

Cipla share price today: The pharma major reported a 49% increase in net profit, reaching Rs 1,571 crore (Image: Reuters) Motilal Oswal has maintained a Neutral rating on Cipla, with a target ...

Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated January 29, 2025.